(169 days)
No
The document describes a standard in-vitro diagnostic analyzer that performs quantitative measurements using established assays. While it mentions "image processing," this is a common technique in many non-AI/ML medical devices for tasks like reading test strips or analyzing samples, and there is no mention of AI, ML, or related concepts like neural networks or training data.
No
Explanation: The device is an in-vitro diagnostic device used for testing and analysis, not for treating or preventing a disease.
Yes
The "Intended Use / Indications for Use" section explicitly states that the "Afinion™ 2 system, consisting of Afinion™ 2 analyzer and Alere Afmion™ test cartridges is for in vitro diagnostic use only." It also describes specific diagnostic uses, such as "quantitative determination of glycated hemoglobin (% hemoglobin A1c, % HbA1c) in human whole blood" for diabetes control, and "quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine" to aid in "early diagnosis of nephropathy."
No
The device description explicitly states it is an "analyzer" and a "new model" of a previously cleared "Analyzer," indicating it is a hardware device. It also mentions "Assay cartridge processing including pumping, heating, image processing," which are hardware-dependent functions.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "Afinion™ 2 system, consisting of Afinion™ 2 analyzer and Alere Afmion™ test cartridges is for in vitro diagnostic use only."
- Analysis of Human Samples: The device is designed to analyze "human whole blood" and "human urine," which are biological samples taken from the human body.
- Diagnostic Purpose: The intended uses for the specific assays (HbA1c and ACR) are for the "quantitative determination" of markers that "aid in the early diagnosis of nephropathy" and are "recommended as a marker of long term metabolic control in persons with diabetes mellitus." These are clear diagnostic purposes.
- Point-of-Care Testing: While performed at the point of care, the analysis is still conducted on samples in vitro (outside the body).
The combination of analyzing human samples in vitro for diagnostic purposes definitively classifies this device as an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Afinion™ 2 analyzer is a compact multi-assay analyzer for point-of-care testing, designed to analyze the Afinion™ test cartridges. Afinion™ 2 system, consisting of Afinion™ 2 analyzer and Alere Afmion™ test cartridges is for in vitro diagnostic use only.
Alere Afinion™ HbA1c is an in-vitro diagnostic test for quantitative determination of glycated hemoglobin (% hemoglobin A1c, % HbA1c) in human whole blood. The measurement of % HbA1c is recommended as a marker of long term metabolic control in persons with diabetes mellitus.
The Alere Afinion™ ACR assay is an in vitro diagnostic test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine the Afinion™ 2 analyzer. The measurement of urine albumin, creatinine and albumin/creatinine ratio, aids in the early diagnosis of nephropathy.
Product codes (comma separated list FDA assigned to the subject device)
LCP, JFY, JQT
Device Description
The Afinion™ 2 analyzer is a multi-assay analyzer for point-of-care testing, designed for use with Alere Afinion™ assays. The Afinion™ 2 analyzer is a modification, a new model, of the previously cleared device Alere Afinion™ AS100 Analyzer.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
point-of-care testing
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation studies were performed as required by risk analysis and all acceptance criteria were met. This device is found to be substantially equivalent to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.7470 Glycosylated hemoglobin assay.
(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
November 21, 2017
Abbott Rapid Diagnostics Annie Wright Senior Regulatory Affairs Manager 9975 Summers Ridge Road San Diego, California 92121
Re: K171650
Trade/Device Name: Alere Afinion™ HbA1c and ACR on Afinion™ 2 analyzer Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Code: LCP, JFY, JQT Dated: June 2, 2017 Received: June 5, 2017
Dear Annie Wright:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR
1
803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Courtney H. Lias -S
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K171650
Device Name
Alere Afinion™ HbA1c and ACR on Afinion™ 2 analyzer
Indications for Use (Describe)
Afinion™ 2 analyzer is a compact multi-assay analyzer for point-of-care testing, designed to analyze the Afinion™ test cartridges. Afinion™ 2 system, consisting of Afinion™ 2 analyzer and Alere Afmion™ test cartridges is for in vitro diagnostic use only.
Alere Afinion™ HbA1c is an in-vitro diagnostic test for quantitative determination of glycated hemoglobin (% hemoglobin A1c, % HbA1c) in human whole blood. The measurement of % HbA1c is recommended as a marker of long term metabolic control in persons with diabetes mellitus.
The Alere Afinion™ ACR assay is an in vitro diagnostic test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine the Afinion™ 2 analyzer. The measurement of urine albumin, creatinine and albumin/creatinine ratio, aids in the early diagnosis of nephropathy.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image contains the logo for Abbott Laboratories. The logo features a stylized, rounded letter "a" in a bright blue color. Below the symbol, the company name "Abbott" is written in a bold, black font. The logo is simple and modern, conveying a sense of trust and reliability.
K171650 510(k) SUMMARY
GENERAL INFORMATION
| Submitter: | Abbott Rapid Diagnostics |
|---|---|
| 9975 Summers Ridge Road | |
| San Diego, CA 92121 USA | |
| Annie Wright | |
| Senior Manager, Regulatory Affair | |
| Phone: (858) 805-2316 | |
| Email: annie.wright@alere.com | |
| Applicant Name: | Abbott Rapid Diagnostics |
| Kjelsaasveien 161 | |
| PO Box 6863 Rodeloekka | |
| NO-0504 Oslo | |
| Norway | |
| Establishment #9613069 |
Date Prepared: November 20, 2017
DEVICE IDENTIFICATION
Trade or Proprietary Names: Alere Afinion™ HbA1c Alere Afinion™ ACR Afinion™ 2
Common Name: HbA1c test ACR test Analyzer
Classification:
| Product Code | Classification | Regulation Section | Classification Panel |
|---|---|---|---|
| LCP | Class II | 21 CFR 864.7470 | Hematology |
| JFY | Class II | 21 CFR 862.1225 | Chemistry |
| JQT | Class I | 21 CFR 862.2400 | Chemistry |
4
Image /page/4/Picture/0 description: The image shows the logo for Abbott, a healthcare company. The logo consists of a stylized letter 'a' in blue, positioned above the company name "Abbott" in black, sans-serif font. The 'a' is designed with a rounded, modern look, and the overall design is clean and professional.
Predicate Device:
Alere Afinion™ HbA1c and Alere Afinion™ AS100 Analyzer (K151809)
The following are the legally marketed devices covered under the predicate device clearance, K151809, and their prior clearances:
The Alere Afinion™ HbA1c assay with HbA1c controls for use with the Alere Afinion™ AS100 Analyzer was cleared under K050574.
The Alere Afinion™ ACR assay with ACR controls for use with the Alere Afinion™ AS100 Analyzer was cleared under K072409.
The system, including both HbA1c and ACR assays and the Afinion AS100 Analyzer, was cleared under K110056 for the addition of a new accessory, the Afinion Data Connectivity Converter.
A modification to the Afinion HbA1c assay with the Afinion AS100 Analyzer was cleared under K151809.
DEVICE DESCRIPTION
The Afinion™ 2 analyzer is a multi-assay analyzer for point-of-care testing, designed for use with Alere Afinion™ assays. The Afinion™ 2 analyzer is a modification, a new model, of the previously cleared device Alere Afinion™ AS100 Analyzer.
INTENDED USE/INDICATIONS FOR USE
Afinion™ 2 analyzer is a compact multi-assay analyzer for point-of-care testing, designed to analyze the Alere Afinion™ test cartridges. Afinion™ 2 system, consisting of Afinion™ 2 analyzer and Alere Afinion™ test cartridges is for in vitro diagnostic use only.
Alere Afinion™ HbA1c is an in-vitro diagnostic test for quantitative determination of glycated hemoglobin (% hemoglobin A1c, % HbA1c) in human whole blood. The measurement of % HbA1c is recommended as a marker of long term metabolic control in persons with diabetes mellitus.
The Alere Afinion™ ACR assay is an in vitro diagnostic test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine using the Afinion™ 2 analyzer. The measurement of urine albumin, creatinine and albumin/creatinine ratio, aids in the early diagnosis of nephropathy.
5
Image /page/5/Picture/0 description: The image contains the logo for Abbott, a healthcare company. The logo features a stylized letter 'A' in blue, positioned above the company name 'Abbott' in bold, black font. The 'A' is designed with rounded edges, giving it a modern and approachable look. The overall design is clean and professional, reflecting the company's focus on health and innovation.
COMPARISON WITH PREDICATE
| Attribute | Predicate Device
Alere Afinion™ AS100
Analyzer
K151809 | Candidate Device
Alere Afinion™ HbA1c and
ACR on Afinion™ 2 analyzer |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Similarities | | |
| Intended use | Alere Afinion™ 2 is a compact
multi-assay analyzer for point-of-
care testing, designed to analyze the
Afinion™ test cartridges. | Same |
| Analyzer function | Assay cartridge processing
including pumping, heating, image
processing | Same |
| Cartridge interface | Physical processing of cartridge
(locking, docking, splitting, foil
penetration, merging) | Same |
| User Interface | User display and operating
instructions in labeling | Same |
| Peripheral units | A barcode reader and printer can be
connected | Same |
| Differences | | |
| Components | Most components in metal | Several metal components replaced
with injection molded plastics |
| Electronics | Obsolete components or
components that will be obsolete in
near future, e.g. CPU and memory. | Obsolete components replaced by
those with more current technology |
| | 14 PCBs in use | 9 PCBs in use |
| Dimensions | 190 mm W x 170 mm H x 340 mm D
5 kg | 200 mm W x 186 mm H x 328 mm D
3.4 kg |
| Connectivity | Separate connectivity unit with
Ethernet plug | Ethernet plug incorporated into the
analyzer and connectivity software
incorporated in the software |
DESCRIPTION OF DEVICE MODIFICATION
The Alere Afinion™ HbA1c and ACR on Afinion™ 2 analyzer has the same functionality and user interface as the Alere Afinion™ AS100 Analyzer. The intended use/indications for use and fundamental scientific technology have not changed. The primary modifications are changes in component materials and other minor changes in component design in order to make a more robust analyzer. Electronic components that
6
Image /page/6/Picture/0 description: The image shows the logo for Abbott Laboratories. The logo consists of a stylized, rounded letter "a" in blue, positioned above the word "Abbott" in a bold, sans-serif font. The color of the text is black.
are obsolete or expected to become obsolete in the near future were changed. Software overall architecture and high-level requirements remain unchanged from the Alere Afinion™ AS 100 Analyzer to the Afinion™ 2 analyzer. Software design in the Afinion™ 2 analyzer was modified from the Alere Afinion™ AS 100 Analyzer wherever needed to adapt to changes made to electronics and mechanics in order to maintain assay sequence timing as it is in the Alere Afinion™ AS100 Analyzer.
DESIGN CONTROL ACTIVITIES
The design development and verification/validation of the device modification have been performed under design control. The design control activities were based on risk analysis, and acceptance criteria were set to maintain the performance and safety of the Afinion™ system using the applicable Alere Afinion™ tests with the device. All requirements for Alere Afinion™ AS100 Analyzer have been re-verified for Afinion™ 2 analyzer through tests both at system level and discipline level (electronics, mechanics and software). The risk analysis identified the appropriate in-house analytical performance verification studies to demonstrate that the analytical performance and risk of erroneous results for Alere Afinion™ HbA1c and Alere Afinion™ ACR are not adversely affected by using the modified device.
CONCLUSION
Verification and validation studies were performed as required by risk analysis and all acceptance criteria were met. This device is found to be substantially equivalent to the predicate device.